Covid-19 roundup: Sinovac shot completely prevents severe cases at 14-day mark, company says
Sinovac has made some big data claims on its way to a tentative approval in China for its Covid-19 vaccine. New Phase III data show promising results in preventing severe disease, but will it be enough to convince international regulators?
Phase III trials of the vaccine, also called CoronaVac, began back in July and were ongoing in Brazil, Turkey, Indonesia and Chile using a 0/14 day schedule with a total enrollment of 25,000 participants.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.